Best semaglutide providers — and when the answer is Wegovy
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The semaglutide market's defining fact in 2026 is how close the approved product has come: Wegovy at $349 cash ($199 intro), the pill from $149. Against that, the compounded picks: overall floor Oak Longevity at $133 — with its state limits stated plainly; broad-availability floor Yucca Health↗ at $146; dose-flat, no-membership pick NexLife↗ at $165, where the 2.4 mg month costs what the 0.25 mg month cost; membership-bundle pick Mochi at $178 all-in, where the $79 fee buys unlimited video visits people actually use.
The honest tiebreaker: if the program you like is within $203/month of Wegovy, read the brand comparison before deciding — at that gap, the approved product's manufacturing oversight is the cheapest thing on the page.
RANK01
Oak Longevity
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
SOURCE-VERIFIED · captured 2026-08-08
$133/MO ALL-IN
RANK02
Yucca Health
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$146/MO ALL-IN
RANK04
OrderlyMeds
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$149/MO ALL-IN
RANK05
NexLife
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$165/MO ALL-IN
RANK06
Lavender Sky Health
$25/mo membership already inside the figure; shipping included.
$174/MO ALL-IN
RANK07
Fridays
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
THIRD-PARTY REPORTED · captured 2026-08-05
$175/MO ALL-IN
RANK08
Mochi Health
Dose-flat — the maintenance price equals the starter price; $79/mo membership already inside the figure; shipping included.
$178/MO ALL-IN
Sublingual semaglutide tiers ($199 at NexLife, ~$179 at Henry) rank in the needle-free lane, where the absorption-evidence problem is stated rather than footnoted.
The leaders, across a full year
Monthly figures flatter everyone equally; a year separates them. The field, annualized on the same all-in basis: Oak Longevity: $1,596 monthly-billed; Yucca Health: $1,752 monthly-billed; IVIM Health↗: $1,788 monthly-billed; OrderlyMeds↗: $1,788 monthly-billed; NexLife: $1,980 monthly-billed, $1,740 on its prepaid path (upfront); Lavender Sky Health↗: $2,088 monthly-billed; Fridays: $2,100 monthly-billed; Mochi Health↗: $2,136 monthly-billed.
Spread top-to-bottom within just these five: $540 a year — before considering the rest of the field, where the verified ceiling reaches $2,136. Prepaid paths shrink the totals and add commitment; the trade is priced properly in the annual-cost analysis and at your own numbers in the calculator.
Structure census across the 8 priced programs above: 6 are dose-flat, 5 carry no membership, 2 name their pharmacy network, and 1 publish a prepaid path below their own monthly-billed year. Those four counts are the shape of this list — the price column tells you what a program charges; the census tells you what kind of thing it is.
How to use a list like this well: shortlist two or three, pull each provider page, and read the record — structure, exit terms, pharmacy transparency, evidence flags — before letting the price column decide. The ranking gets you to the right neighborhood; the records keep you out of the wrong house.
Frequently asked
What is the cheapest option on this list?
Oak Longevity at $133 per month all-in on the maintenance basis, captured 2026-08-08. Every figure here is medication plus mandatory fees; confirm at the provider's checkout before enrolling.
How is this ranking produced?
By sorting the public dataset on verified all-in monthly price at the maintenance dose — no editorial reordering, no paid placement. Basis, exclusions, and verification cycle: /methodology/; recompute it yourself from the JSON.
Are compounded GLP-1s on this page FDA-approved?
No compounded product is FDA-approved. Since 2025 compounded tirzepatide and semaglutide are limited to patient-specific 503A prescriptions with documented clinical need; brand options (Zepbound, Wegovy) are the approved products. Regulatory timeline: here.